CIK 0000818686 · Large accelerated filer
TEVA PHARMACEUTICAL INDUSTRIES LTD
Sign in to watch- Ticker
- TEVA
- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- Israel
- Entity type
- operating
- Phone
- 972 (3) 914-8213
- Business address
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED, 124 DVORA HANEVI'A ST., TEL AVIV, Israel
- Former names
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $33,923,078
- in 11 filings, $11.2M under 10b5-1 plans
Net −$33,923,078. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-05-14 | Lippman Evan EVP, Business Development | Option exercise 10b5-1 | +11,841 | 11,841 | ||
| 2026-05-14 | Lippman Evan EVP, Business Development | Sale 10b5-1 | −5,746 | $35.58 | $204K | 6,095 |
| 2026-05-14 | Lippman Evan EVP, Business Development | Option exercise 10b5-1 | +74,008 | 80,103 | ||
| 2026-05-14 | Lippman Evan EVP, Business Development | Sale 10b5-1 | −35,912 | $35.58 | $1.3M | 44,191 |
| 2026-05-14 | Lippman Evan EVP, Business Development | Option exercise · Restricted Share Units 10b5-1 | −11,841 | 35,524 | ||
| 2026-05-14 | Lippman Evan EVP, Business Development | Option exercise · Restricted Share Units 10b5-1 | −74,008 | 74,008 | ||
| 2026-05-14 | Kalif Eliyahu Sharon EVP, Chief Financial Officer | Sale 10b5-1 | −153,251 | $35.61 | $5.5M | 172,184 |
| 2026-05-06 | Weiss Amir Chief Accounting Officer | Sale | −10,679 | $36.00 | $384K | 20,016 |
| 2026-05-05 | Daniell Richard EVP, Europe Commercial | Sale | −30,000 | $35.40 | $1.1M | 55,755 |
| 2026-05-01 | Sabag Mark See "Remarks" | Sale | −144,180 | $34.99 | $5.0M | 80,760 |
| 2026-04-30 | Fox Christine EVP, U.S. Commercial | Sale | −21,258 | $35.31 | $751K | 63,647 |
| 2026-03-17 | Sabag Mark See "Remarks" | Sale | −62,102 | $30.14 | $1.9M | 224,940 |
| 2026-03-05 | Sabag Mark See "Remarks" | Option exercise | +15,723 | 287,042 | ||
| 2026-03-05 | Sabag Mark See "Remarks" | Option exercise · Restricted Share Units | −15,723 | 47,170 | ||
| 2026-03-05 | Kalif Eliyahu Sharon EVP, Chief Financial Officer | Option exercise | +19,916 | 325,435 | ||
| 2026-03-05 | Kalif Eliyahu Sharon EVP, Chief Financial Officer | Option exercise · Restricted Share Units | −19,916 | 59,748 | ||
| 2026-03-05 | Weiss Amir Chief Accounting Officer | Option exercise | +3,537 | 30,695 | ||
| 2026-03-05 | Weiss Amir Chief Accounting Officer | Option exercise · Restricted Share Units | −3,537 | 10,613 | ||
| 2026-03-05 | Francis Richard D President and CEO | Option exercise 10b5-1 | +42,452 | 1,190,664 | ||
| 2026-03-05 | Francis Richard D President and CEO | Sale 10b5-1 | −20,025 | $31.67 | $634K | 1,170,639 |
Page 5 of 64 · 1,279 trades